[Meningococcal purpura fulminans: treatment with recombinant protein C activator in 3 cases]. 2007

U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
Servicio de Anestesiología y Reanimación, Hospital de Basurto, Bilbao, Bizkaia. unaisalinas@yahoo.es

Purpura fulminans is a serious disease associated with high rates of morbidity and mortality. It usually leads to disseminated intravascular coagulation and septic shock related to reduced levels of protein C. Recombinant protein C (rPC) activator has been used successfully to inhibit this process. Intracranial hemorrhages are the most important, life-threatening adverse effects of treatment with rPC activator. We report 3 cases of patients with meningococcal purpura fulminans who developed septic shock and multiorgan dysfunction. They were treated with the protocol for septic shock, antibiotics and rPC activator from the time of admission, and improvement in hemodynamic dysfunction was observed within hours in all patients. All received platelet replacement transfusions. Subarachnoid bleeding complications occurred in 2 patients. One patient died 5 days after admission and 2 were discharged from the intensive recovery care unit 28 days after admission.

UI MeSH Term Description Entries
D008297 Male Males
D008589 Meningococcal Infections Infections with bacteria of the species NEISSERIA MENINGITIDIS. Meningococcal Septicemia,Infections, Meningococcal,Meningococcal Disease,Infection, Meningococcal,Meningococcal Diseases,Meningococcal Infection,Septicemia, Meningococcal
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D011695 IgA Vasculitis A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections. Allergic Purpura,Anaphylactoid Purpura,Henoch Purpura,Henoch-Schoenlein Purpura,Purpura Hemorrhagica,Purpura, Nonthrombocytopenic,Purpura, Schoenlein-Henoch,Rheumatoid Purpura,Schoenlein-Henoch Purpura,Vasculitis, Hemorrhagic,Henoch Schonlein Purpura,Henoch-Schonlein Purpura,Purpura, Nonthrombopenic,Purpura, Schonlein-Henoch,Hemorrhagic Vasculitis,Hemorrhagica, Purpura,Henoch Schoenlein Purpura,Henoch Schonlein Purpuras,Henoch-Schonlein Purpuras,Nonthrombocytopenic Purpura,Nonthrombopenic Purpura,Nonthrombopenic Purpuras,Purpura, Allergic,Purpura, Anaphylactoid,Purpura, Henoch,Purpura, Henoch Schonlein,Purpura, Henoch-Schoenlein,Purpura, Henoch-Schonlein,Purpura, Rheumatoid,Purpura, Schoenlein Henoch,Purpura, Schonlein Henoch,Purpuras, Henoch Schonlein,Purpuras, Henoch-Schonlein,Purpuras, Nonthrombopenic,Purpuras, Schonlein-Henoch,Schoenlein Henoch Purpura,Schonlein Purpura, Henoch,Schonlein Purpuras, Henoch,Schonlein-Henoch Purpura,Schonlein-Henoch Purpuras,Vasculitis, IgA
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
September 2004, Anales de pediatria (Barcelona, Spain : 2003),
U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
June 1997, Critical care medicine,
U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
May 1998, Critical care medicine,
U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
May 1998, Critical care medicine,
U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
May 1998, Critical care medicine,
U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
June 1997, Critical care medicine,
U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
August 2004, Critical care medicine,
U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
March 1998, Lancet (London, England),
U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
March 1998, Lancet (London, England),
U Salinas, and J Unzueta, and M A Vidarte, and M P Rodrigo, and J J Gómez, and L Aguilera
March 1998, Lancet (London, England),
Copied contents to your clipboard!